CI vs VIR · P/E 2.4, rev $274.90B vs rev $74.2M
Cigna Corp (CI) versus Vir Biotechnology Inc (VIR) — a side-by-side from cached financials, not a winner call.
Cigna Corp (CI) is a healthcare plans company listed on US.
Vir Biotechnology Inc (VIR) is a biotechnology company listed on NASDAQ.
Latest reported CI revenue for 2025-12-31 was $274.90B. Net income was $5.96B. Revenue was up 11.2% from 2024-12-31 to 2025-12-31. CI currently screens at market cap $71.62B and trailing P/E 2.4.
Latest reported VIR revenue for 2024-12-31 was $74.2M. Net income was -$522.0M. Revenue was down 13.9% from 2023-12-31 to 2024-12-31. VIR currently screens at market cap $1.45B.
CI currently screens at market cap $71.62B and trailing P/E 2.4. VIR currently screens at market cap $1.45B.
Not investment advice. Open the CI and VIR stock pages for the full models.
Not investment advice.